Articles related to CONTRACEPTION/BIRTH CONTROL

Maternal immunization with 2 doses of vaccine was 97% and 53% effective against infant hospitalization from delta and omicron variants, respectively. The effectiveness of the vaccine in preventing infant hospitalization declined by nearly 20% after 16 weeks. Receiving the second dose in the third trimester yielded the greatest benefit.

Emzahh (norethindrone tablets), the progestin-only generic equivalent of the discontinued Ortho Micronor, was approved via an abbreviated NDA.

Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.

In the US, only two emergency contraceptive methods have been FDA approved: oral levonorgestrel and oral ulipristal acetate. However, the copper IUD appears to be an order of magnitude more effective than the approved methods and so copper IUD is often used. But women prefer the levonorgestrel IUD. This study looked to compare the two IUDs as emergency contraceptives. Among 711 women randomized to copper versus levonorgestrel IUDs, pregnancy rates were 1 in 317 in the levonorgestrel group and 0 in 321, equating to non-inferiority for the levonorgestrel IUD.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.

During pregnancy and the postpartum period, the body is subjected to abnormal stress, raising the possibility of eye and vision-related conditions and complications. Refractive changes, central serous chorioretinopathy, Purtscher-like retinopathy, diabetes, hypertension, and immunologic diseases are examples of eye and vision-related conditions and complications. Although diabetic retinopathy that develops during pregnancy usually resolves on its own after delivery, women are still at risk of progression for up to a year after delivery.